{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:20Z","timestamp":1792839740517,"version":"4.5.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The aim of this study was to evaluate the influence of treatment of hepatitis C with sofosbuvir and velpatasvir (SOF\/VEL) on children\u2019s growth.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Fifty children 6-18 years of age were successfully treated for hepatitis C with a 12-week course of SOF\/VEL fixed dose adjusted to the body weight in the PANDAA-PED (Treatment of chronic hepatitis C in children 6\u201318 years of age using a pangenotypic direct-acting antiviral sofosbuvir\/velpatasvir) project. Growth parameters were compared at 1 year after treatment with baseline (at the start of treatment) and 12-week-posttreatment values. Body mass index (BMI), weight and height Z scores adjusted to sex and age were calculated according to the World Health Organization reference data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Forty-nine participants (23 boys and 26 girls) completed all the visits. The mean age at 1 year after treatment was 10.9\u2009\u00b1\u20092.5 years, and all children had undetectable hepatitis C virus RNA at this point. Significant weight and height gains were observed after treatment irrespective of the patients\u2019 age and sex. Height Z scores did not vary significantly both at 12 weeks and 1 year after treatment, confirming a normal increase in participants\u2019 height. Weight Z scores for 16 children below 10 years of age decreased at 1 year after treatment. BMI Z score values decreased at 12 weeks after treatment compared to the baseline in boys, but no difference was found between 1-year posttreatment and baseline BMI Z scores in both girls and boys.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Results of the PANDAA-PED study showed normal growth up to 1 year after successful treatment with SOF\/VEL in children 6-18 years of age. Despite the decrease in BMI Z score in boys observed at 12 weeks after treatment, no differences were found between baseline and 1-year posttreatment values. Our observations confirm the long-term safety of the SOF\/VEL treatment in children 6-18 years of age.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004504","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T20:43:41Z","timestamp":1725482621000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["The Influence of Treatment With Sofosbuvir\/Velpatasvir on Children\u2019s Growth\u2014Results of the PANDAA-PED Study"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7783-6904","authenticated-orcid":false,"given":"Maria","family":"Pokorska-\u015apiewak","sequence":"first","affiliation":[{"name":"From the Department of Children\u2019s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland"},{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Talarek","sequence":"additional","affiliation":[{"name":"From the Department of Children\u2019s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland"},{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Aniszewska","sequence":"additional","affiliation":[{"name":"From the Department of Children\u2019s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland"},{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Pluta","sequence":"additional","affiliation":[{"name":"From the Department of Children\u2019s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland"},{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dobrzeniecka","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Marczy\u0144ska","sequence":"additional","affiliation":[{"name":"From the Department of Children\u2019s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland"},{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Indolfi","sequence":"additional","affiliation":[{"name":"Department of Neurofarba, Meyer Children\u2019s University of Florence, Florence, Italy"},{"name":"Meyer Children\u2019s Hospital, Istituto di Ricerca e Cura a Carattere Scientifico, Florence, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"R1-20250131","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/liv.15827","article-title":"Efficacy and safety of DAA in children and adolescents with chronic HCV infection: a systematic review and meta-analysis.","volume":"44","author":"Indolfi","year":"2024","journal-title":"Liver Int"},{"key":"R2-20250131","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection.","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"R3-20250131","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/liv.14537","article-title":"Global real-world evidence of sofosbuvir\/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts.","volume":"40","author":"Mangia","year":"2020","journal-title":"Liver Int"},{"key":"R4-20250131","doi-asserted-by":"crossref","first-page":"e0215783","DOI":"10.1371\/journal.pone.0215783","article-title":"SVR12 rates higher than 99% after sofosbuvir\/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: a real world experience.","volume":"14","author":"Mangia","year":"2019","journal-title":"PLoS One"},{"key":"R6-20250131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/TCRM.S326099","article-title":"Profile of sofosbuvir and velpatasvir combination in the treatment of chronic hepatitis C in children and adolescents: current evidence.","volume":"20","author":"Brigham","year":"2024","journal-title":"Ther Clin Risk Manag"},{"key":"R7-20250131","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/liv.15637","article-title":"Efficacy and safety of treatment with sofosbuvir\/velpatasvir in patients aged 6-18 years with chronic hepatitis C-Results of the PANDAA-PED study.","volume":"43","author":"Pokorska-\u015apiewak","year":"2023","journal-title":"Liver Int"},{"key":"R8-20250131","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/jpn3.12160","article-title":"ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource-limited settings.","volume":"78","author":"Indolfi","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R9-20250131","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/jpn3.12045","article-title":"Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection.","volume":"78","author":"Jonas","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R10-20250131","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/hep.25690","article-title":"Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial.","volume":"56","author":"Jonas","year":"2012","journal-title":"Hepatology"},{"key":"R11-20250131","doi-asserted-by":"crossref","first-page":"e0209615","DOI":"10.1371\/journal.pone.0209615","article-title":"Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.","volume":"13","author":"Kawagishi","year":"2018","journal-title":"PLoS One"},{"key":"R12-20250131","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/hepr.13899","article-title":"Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight.","volume":"53","author":"Tokuchi","year":"2023","journal-title":"Hepatol Res"},{"key":"R13-20250131","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3390\/diagnostics12030702","article-title":"Changes in liver steatosis using controlled attenuation parameter among patients with chronic hepatitis C infection treated with direct-acting antivirals therapy who achieved sustained virological response.","volume":"12","author":"Trifan","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R14-20250131","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1038\/s41598-021-93251-3","article-title":"Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis.","volume":"11","author":"Villani","year":"2021","journal-title":"Sci Rep"},{"key":"R15-20250131","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/17474124.2021.1963231","article-title":"Sofosbuvir\/velpatasvir for the treatment of hepatitis C in pediatric patients.","volume":"15","author":"Rubino","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R16-20250131","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/v14030474","article-title":"The influence of treatment with ledipasvir\/sofosbuvir on growth parameters in children and adolescents with chronic hepatitis C.","volume":"14","author":"Pokorska-\u015apiewak","year":"2022","journal-title":"Viruses"},{"key":"R17-20250131","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MPG.0000000000002900","article-title":"Efficacy of sofosbuvir\/ledipasvir in adolescents with chronic hepatitis C genotypes 1, 3, and 4: a real-world study.","volume":"72","author":"Serranti","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R18-20250131","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/INF.0000000000002189","article-title":"The effectiveness of ledipasvir\/sofosbuvir in youth with genotype 4 hepatitis C virus: a single Egyptian Center Study.","volume":"38","author":"Fouad","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R19-20250131","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/MEG.0000000000001360","article-title":"Effectiveness of 8-week sofosbuvir\/ledipasvir in the adolescent chronic hepatitis C-infected patients.","volume":"31","author":"El-Khayat","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R20-20250131","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1097\/INF.0000000000002222","article-title":"Effects of dual sofosbuvir\/daclatasvir therapy on weight and linear growth in adolescent patients with chronic hepatitis C virus infection.","volume":"38","author":"Yakoot","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R21-20250131","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.30840","article-title":"Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study.","volume":"71","author":"Jonas","year":"2020","journal-title":"Hepatology"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T13:02:14Z","timestamp":1738328534000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004504","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]}}}